| Literature DB >> 27863655 |
Ramesh Soundararajan1, Kenji Sasaki1, Lisa Godfrey1, Uchechukwu Odunze1, Nancy Fereira1, Andreas Schätzlein2, Ijeoma Uchegbu3.
Abstract
Here we examine the mechanisms by which nanoparticles enable the oral absorption of water-insoluble, P-glycoprotein efflux pump (P-gp) substrates, without recourse to P-gp inhibitors. Both 200nm paclitaxel N-(2-phenoxyacetyl)-6-O-glycolchitosan (GCPh) nanoparticles (GCPh-PTX) and a simulated Taxol formulation, facilitate drug dissolution in biorelevant media, unlike paclitaxel nanocrystals. Verapamil (40mgkg-1) increased the oral absorption from low dose Taxol (6 or 10mgkg-1) by 100%, whereas the oral absorption from high dose Taxol (20mgkg-1) or low dose GCPh-PTX (6 or 10mgkg-1) was largely unchanged by verapamil. There was virtually no absorption from control paclitaxel nanocrystals (20mgkg-1). Imaging of ex-vivo rat ileum samples showed that fluorescently labelled GCPh nanoparticles are mucoadhesive and are taken up by ileum epithelial cells. GCPh nanoparticles were also found to open Caco-2 cell tight junctions. In conclusion, mucoadhesive, drug solubilising GCPh nanoparticles enable the oral absorption of paclitaxel via the saturation of the P-gp pump (by high local drug concentrations) and by particle uptake and tight junction opening mechanisms.Entities:
Keywords: Absorption; Biopharmaceutical Classification System; Chitosan amphiphile; N-(2-phenoxyacetamide)-6-O-glycolchitosan; Nanoparticle; Oral; Paclitaxel
Mesh:
Substances:
Year: 2016 PMID: 27863655 DOI: 10.1016/j.ijpharm.2016.08.013
Source DB: PubMed Journal: Int J Pharm ISSN: 0378-5173 Impact factor: 5.875